Legacy Academic Services Revenue -- $55 million in Q4, with the segment now managed specifically for free cash flow generation. Free Cash Flow -- Negative $15 million in Q4, primarily impacted by $12 ...
With the rise of models such as ChatGPT, Microsoft Copilot, Claude, and Google Gemini, more college students than ever are using generative AI tools to help ...
Small creators are increasingly relying on website-based learning tools to share knowledge and build steady revenue streams.
Trump’s history is off — the eagles he references are actually part of a bridge connecting Virginia and Washington that was ...
The Indian law firm market is experiencing an existential churn. Managing partners and senior leadership at law firms are grappling with restructuring their models from a collection of individual ...
Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...
Neuroscientists have detected five broad phases of brain structure in the average human life, split up by four pivotal turning points between birth and death when our brains reconfigure. Childhood ...
Choosing a business structure may not be the most glamorous part of starting a business. In fact, it can actually feel a little daunting. But the business structure you choose can affect how you pay ...
aDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK bSocial, Genetic & Developmental Psychiatry Centre, Institute ...
We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Michael is a former senior editor of investing and trading products for ...
We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Michael is a former senior editor of investing and trading products for ...
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results